Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

These include systemic inflammatory autoimmune diseases, leukemia cutis and lysozyme-induced nephropathy; the latter requires close monitoring of renal function during leukocytosis and is a potential indication for cytoreductive therapy.